성기능 장애 치료제 시장 : 세계 예측(2026-2032년)

The Drugs for Sexual Dysfunction Market is projected to grow by USD 9.14 billion at a CAGR of 8.18% by 2032.

Drugs for Sexual Dysfunction: Executive Summary

Drugs for sexual dysfunction address conditions affecting sexual desire, arousal, erectile function, ejaculation, and related performance concerns. Their use is shaped by clinical guidelines, diagnosis rates, patient willingness to seek care, safety considerations, and access to qualified prescribers. Treatment decisions increasingly emphasize underlying cardiovascular, metabolic, hormonal, neurological, psychological, and medication-related factors rather than symptom relief alone.

Clinical Integration Is Reshaping Treatment Pathways

The landscape is shifting toward more individualized care, earlier assessment of comorbidities, and combination management involving medicines, behavioral interventions, counseling, and lifestyle changes. Regulatory scrutiny, contraindication screening, pharmacovigilance, and attention to counterfeit or unsafe products remain central to patient protection. Digital consultations and pharmacy services may improve convenience, but they also require robust identity verification, prescribing controls, and continuity of care.

Artificial Intelligence Can Improve Discovery, Triage, and Safety

Artificial intelligence can support clinical documentation, symptom triage, interaction screening, adherence support, and identification of patients who may benefit from evaluation of underlying disease. In research and development, it can assist with evidence synthesis, trial recruitment, and analysis of treatment-response patterns. Effective deployment requires representative data, clinician oversight, explainable outputs, privacy safeguards, and monitoring for bias; AI should complement rather than replace medical diagnosis or prescribing judgment.

Regional Insights: Uneven Access and Distinct Care Contexts

North America combines comparatively developed specialty care and digital-health infrastructure with affordability, insurance, and privacy challenges. Europe is influenced by coordinated regulatory standards alongside differing national reimbursement and prescribing pathways. Asia-Pacific presents substantial diversity in healthcare access, aging patterns, urbanization, and cultural attitudes toward sexual health. Latin America continues to face uneven specialist availability and out-of-pocket barriers, while the Middle East reflects varied regulatory environments and social sensitivities. Africa's priorities include essential-medicine access, primary-care capacity, public-health integration, and protection against falsified products.

Group Insights: Policy Alignment and Health-System Capacity

ASEAN markets require approaches that accommodate differing regulatory systems, income levels, and healthcare infrastructure. BRICS members span major differences in domestic production, public provision, private care, and diagnostic capacity. The European Union benefits from regulatory coordination but retains national variation in reimbursement and clinical practice. G7 systems generally have stronger research and specialist networks, while still addressing affordability, aging populations, and equitable access. GCC countries are investing in healthcare modernization, with demand shaped by expatriate populations and national health strategies. NATO members represent diverse health systems, making alliance membership less informative than national regulation, procurement, and clinical access conditions.

Country Insights: Diverse Regulatory and Care Pathways

Australia and Canada combine established healthcare systems with geographic access challenges. Brazil and Mexico face substantial regional variation in specialist care, affordability, and product quality oversight. China and India are characterized by large, diverse patient populations and evolving digital and regulatory ecosystems. Japan, South Korea, and the European countries of France, Germany, Italy, Spain, and the United Kingdom differ in reimbursement, prescribing norms, and integration between primary and specialist care. Russia's treatment environment is shaped by regulatory, economic, and healthcare-access conditions. The United States has broad specialist and telehealth availability but significant variation in coverage, out-of-pocket costs, and care continuity.

Action Priorities for Industry Leaders

Leaders should prioritize clinically responsible access by strengthening evidence generation, clear labeling, contraindication education, and post-market safety monitoring. Build partnerships with healthcare professionals and digital providers that preserve prescribing standards and patient privacy. Tailor education and distribution to local regulations, language, health literacy, and care capacity rather than applying a uniform global model. Invest in supply-chain authentication and quality controls, and use real-world evidence to identify adherence barriers and underserved populations. AI initiatives should begin with narrowly defined, auditable use cases and measurable clinical-safety outcomes.

Research Methodology: Evidence-Led Market Assessment

This executive summary uses the defined market scope of drugs for sexual dysfunction and organizes findings across clinical, regulatory, technological, demographic, and healthcare-access dimensions. The assessment framework emphasizes publicly verifiable sources such as regulatory communications, clinical guidelines, peer-reviewed research, health-system publications, and official country or regional policy documents. Insights are synthesized comparatively across the specified regions, groups, and countries, without presenting market estimates, market shares, forecasts, or company-specific analysis.

Conclusion: Responsible Access Will Define Progress

The sector's direction will be determined by how effectively treatment is integrated with diagnosis of underlying conditions, patient-centered counseling, safety oversight, and equitable access. Regional and country differences make localization essential, while digital tools and AI can improve navigation and monitoring when governed responsibly. Industry leaders that combine rigorous evidence, trusted supply, compliant delivery, and measurable patient benefit will be best positioned to support safer and more effective sexual-health care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drugs for Sexual Dysfunction Market, by Drug Class

• 7.1. Introduction
• 7.2. Hormone Therapy
  • 7.2.1. Estrogen Therapy
  • 7.2.2. Testosterone Therapy
• 7.3. Pde5 Inhibitors
  • 7.3.1. Cialis (Tadalafil)
  • 7.3.2. Levitra (Vardenafil)
  • 7.3.3. Stendra (Avanafil)
  • 7.3.4. Viagra (Sildenafil)
• 7.4. Topical Agents
  • 7.4.1. Creams
  • 7.4.2. Gels
  • 7.4.3. Ointments

8. Drugs for Sexual Dysfunction Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intracavernosal Injection
  • 8.2.2. Intramuscular Injection
• 8.3. Oral
• 8.4. Topical

9. Drugs for Sexual Dysfunction Market, by Indication

• 9.1. Introduction
• 9.2. Erectile Dysfunction
  • 9.2.1. Organic Erectile Dysfunction
  • 9.2.2. Psychogenic Erectile Dysfunction
• 9.3. Female Sexual Dysfunction
  • 9.3.1. Hypoactive Sexual Desire Disorder
  • 9.3.2. Sexual Arousal Disorder

10. Drugs for Sexual Dysfunction Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
  • 10.3.1. Manufacturer-Owned
  • 10.3.2. Third-Party Owned
• 10.4. Retail Pharmacy

11. Drugs for Sexual Dysfunction Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Drugs for Sexual Dysfunction Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Drugs for Sexual Dysfunction Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Aurobindo Pharma Limited
• 15.2. Bayer AG
• 15.3. Cipla Limited
• 15.4. Dr. Reddy's Laboratories Ltd.
• 15.5. Eli Lilly and Company
• 15.6. Endo International plc
• 15.7. Futura Medical plc
• 15.8. GlaxoSmithKline plc (GSK)
• 15.9. Hims & Hers Health, Inc.
• 15.10. Lupin Limited
• 15.11. Petros Pharmaceuticals, Inc.
• 15.12. Pfizer Inc.
• 15.13. Sanofi S.A.
• 15.14. SK Inc.
• 15.15. Sun Pharmaceutical Industries Ltd.
• 15.16. Teva Pharmaceutical Industries Ltd.
• 15.17. Viatris Inc.
• 15.18. VIVUS LLC

16. Key Experts